English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/135558
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival

AuthorsMoreno, María José; Alcoceba, Miguel; Blanco, Óscar; González, Marcos ; Mangues, Ramon; Casanova, Isolda
KeywordsCXCR4
Cell dissemination
Prognostic marker
Cell migration
Diffuse large B cell lymphoma
Issue Date2015
PublisherJohn Wiley & Sons
CitationJournal of Pathology 235(3): 445-455 (2015)
AbstractThe chemokine receptor CXCR4 has been implicated in the migration and trafficking of malignant B cells in several haematological malignancies. Over-expression of CXCR4 has been identified in haematological tumours, but data concerning the role of this receptor in diffuse large B cell lymphoma (DLBCL) are lacking. CXCR4 is a marker of poor prognosis in various neoplasms, correlating with metastatic disease and decreased survival of patients. We studied CXCR4 involvement in cell migration in vitro and dissemination in vivo. We also evaluated the prognostic significance of CXCR4 in 94 biopsies of DLBCL patients. We observed that the level of expression of CXCR4 in DLBCL cell lines correlated positively with in vitro migration. Expression of the receptor was also associated with increased engraftment and dissemination, and decreased survival time in NOD/SCID mice. Furthermore, administration of a specific CXCR4 antagonist, AMD3100, decreased dissemination of DLBCL cells in a xenograft mouse model. In addition, we found that CXCR4 expression is an independent prognostic factor for shorter overall survival and progression-free survival in DLBCL patients. These results show that CXCR4 mediates dissemination of DLBCL cells and define for the first time its value as an independent prognostic marker in DLBCL patients.
URIhttp://hdl.handle.net/10261/135558
DOI10.1002/path.4446
Identifiersdoi: 10.1002/path.4446
e-issn: 1096-9896
issn: 0022-3417
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.